글로벌 연구동향
방사선종양학
- 2018년 04월호
[Cell Death Dis.] Synergistic actions of FGF2 and bone marrow transplantation mitigate radiation-induced intestinal injury.충남의대, KAIST/ 김병혁, 정희원, 권진이*, 서재명*
- 출처
- Cell Death Dis.
- 등재일
- 저널이슈번호
- 내용
Abstract
Unwanted radiological or nuclear exposure remains a public health risk for which effective therapeutic countermeasures are lacking. Here, we evaluated the efficacy of fibroblast growth factor-2 (FGF2) in treating radiation-induced gastrointestinal syndrome (RIGS) incurred by lethal whole-body irradiation (WBI) when administered in conjunction with bone marrow transplantation (BMT). In vitro experiments indicated FGF2 treatment increased proliferation, reduced apoptosis, and upregulated AKT-GSK3β/β-catenin signaling in irradiated IEC-6 cells. We next established and analyzed mice cohorts consisting of sham irradiation (Group Sh); 12 Gy WBI (Group A); WBI with BMT (Group B); WBI with FGF2 treatment (Group F); and WBI with BMT and FGF2 treatment (Group BF). At 2 weeks post-irradiation, Group BF showed a dramatic increase in survival over all other groups. Intestinal epithelium of Group BF, but not Group B or F, showed augmented proliferation, decreased apoptosis, and preserved crypt numbers and morphology. Furthermore, Group BF maintained intestinal barrier function with minimal inflammatory disturbances in a manner comparable to Group Sh. In accordance, transcriptomic analyses showed significant upregulation of intestinal barrier and stem cell markers in Group BF relative to Groups A and B. Taken together, parenteral FGF2 synergizes with BMT to confer potent mitigation against RIGS.
Author informationKim BH1,2,3, Jung HW1, Seo SH1, Shin H4, Kwon J5, Suh JM6,7.
1
Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea.
2
Division of Biological Warfare Preparedness and Response, Armed Forces Medical Research Institute, Daejeon, Republic of Korea.
3
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
4
Biomedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, Republic of Korea.
5
Department of Radiation Oncology, Chungnam National University College of Medicine, Daejeon, Republic of Korea. ijeannyi@daum.net.
6
Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea. jmsuh@kaist.ac.kr.
7
Biomedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, Republic of Korea. jmsuh@kaist.ac.kr.
- 덧글달기
- 이전글 [Clin Lung Cancer.] Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
- 다음글 [Radiat Oncol.] Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment.